Instanosis Receives FDA Breakthrough Device Designation for Rapid Xylazine Urine Test
核心洞察
Instanosis Inc. (搜索) announced that its Xylazine Rapid Test (Urine) has received FDA Breakthrough Device Designation, marking a significant milestone for rapid diagnostic tools addressing emerging drug threats.
Xylazine, a veterinary sedative not approved for human use, has become increasingly prevalent in the illicit drug supply and is frequently combined with fentanyl and other synthetic opioids.
The rapid test is designed to provide quick detection of xylazine in urine samples to support healthcare providers, laboratories, and public health professionals in identifying potential exposure.
Instanosis Inc. (搜索) announced that its Xylazine Rapid Test (Urine) has been granted Breakthrough Device Designation by the U.S. Food and Drug Administration (FDA), representing a significant milestone in the development of rapid diagnostic tools addressing emerging drug threats.
The designation comes as xylazine, a veterinary sedative not approved for human use, has become increasingly prevalent in the illicit drug supply across the United States. The substance is frequently identified in combination with fentanyl and other synthetic opioids and has been associated with severe respiratory depression (搜索), prolonged sedation, and complex soft tissue injury (搜索).
Critical Clinical Need
Because naloxone does not reverse the effects of xylazine, identifying its presence is critical for informing clinical assessment and patient monitoring. This limitation creates significant challenges for healthcare providers treating patients with suspected opioid overdoses, as standard reversal agents may be ineffective against xylazine's effects.
The Instanosis Xylazine Rapid Test (Urine) is designed to provide rapid detection of xylazine in urine samples. The device is intended to support healthcare providers, laboratories, and public health professionals in identifying potential exposure and improving awareness of evolving substance patterns.
Regulatory Pathway
The FDA's Breakthrough Device Designation program is intended to expedite the development and review of medical devices that may offer more effective diagnosis or treatment of life-threatening or irreversibly debilitating conditions. Through this designation, Instanosis will receive prioritized interaction and review as the company advances the device through its regulatory pathway.
"The FDA's Breakthrough Device Designation is a significant milestone for our development program," said Dr. Xiaofeng Xia, Chief Operating Officer of Instanosis. "This designation enables enhanced interaction with the Agency as we execute our clinical and regulatory strategy to deliver a reliable, rapid xylazine detection solution to the market."
Company Focus
Instanosis, a Pennsylvania-based diagnostics company, remains dedicated to building science-driven diagnostic technologies that address dynamic public health and clinical challenges in a rapidly changing healthcare environment. The company is committed to developing rapid testing technologies for use in clinical and community settings, advancing innovative detection solutions designed to support healthcare providers, public health agencies, and frontline stakeholders nationwide.